Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Goodwin

Showing results (811-820 of 851) with videos related to

Pageof 86
Sort By:
Molecular Cancer Therapeutics|September 20, 2019
Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses PreclinicallyLucy C Riches, Antonio G Trinidad, Gareth Hughes, et al.
Plos One|August 25, 2020
An iron-dependent metabolic vulnerability underlies VPS34-dependence in RKO cancer cellsMarek J Kobylarz, Jonathan M Goodwin, Zhao B Kang, et al.
Trials|November 25, 2017
The effects of using the PReDicT Test to guide the antidepressant treatment of depressed patients: study protocol for a randomised controlled trialJonathan Kingslake, Rebecca Dias, Gerard R Dawson, et al.
Science Signaling|December 19, 2023
RHOA<sup>L57V</sup> drives the development of diffuse gastric cancer through IGF1R-PAK1-YAP1 signalingAntje Schaefer, Richard G Hodge, Haisheng Zhang, et al.
Global Health, Science and Practice|March 15, 2019
Addressing the Third Delay in Saving Mothers, Giving Life Districts in Uganda and Zambia: Ensuring Adequate and Appropriate Facility-Based Maternal and Perinatal Health CareDiane Morof, Florina Serbanescu, Mary M Goodwin, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|February 27, 2021
The clinical effectiveness of using a predictive algorithm to guide antidepressant treatment in primary care (PReDicT): an open-label, randomised controlled trialMichael Browning, Amy C Bilderbeck, Rebecca Dias, et al.
Cancer Research|November 8, 2022
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic CancerCraig M Goodwin, Andrew M Waters, Jennifer E Klomp, et al.
Science Signaling|August 9, 2022
Functional and biological heterogeneity of KRAS<sup>Q61</sup> mutationsMinh V Huynh, G Aaron Hobbs, Antje Schaefer, et al.
Science Advances|October 1, 2021
GABARAP sequesters the FLCN-FNIP tumor suppressor complex to couple autophagy with lysosomal biogenesisJonathan M Goodwin, Ward G Walkup, Kirsty Hooper, et al.
FEBS Letters|November 24, 2016
Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitorsTaekyu Lee, Zhiguo Bian, Bin Zhao, et al.
Pageof 86

Showing results (811-820 of 851) with videos related to

Sort By:
Pageof 86
Molecular Cancer Therapeutics|September 20, 2019
Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses PreclinicallyLucy C Riches, Antonio G Trinidad, Gareth Hughes, et al.
Plos One|August 25, 2020
An iron-dependent metabolic vulnerability underlies VPS34-dependence in RKO cancer cellsMarek J Kobylarz, Jonathan M Goodwin, Zhao B Kang, et al.
Trials|November 25, 2017
The effects of using the PReDicT Test to guide the antidepressant treatment of depressed patients: study protocol for a randomised controlled trialJonathan Kingslake, Rebecca Dias, Gerard R Dawson, et al.
Science Signaling|December 19, 2023
RHOA<sup>L57V</sup> drives the development of diffuse gastric cancer through IGF1R-PAK1-YAP1 signalingAntje Schaefer, Richard G Hodge, Haisheng Zhang, et al.
Global Health, Science and Practice|March 15, 2019
Addressing the Third Delay in Saving Mothers, Giving Life Districts in Uganda and Zambia: Ensuring Adequate and Appropriate Facility-Based Maternal and Perinatal Health CareDiane Morof, Florina Serbanescu, Mary M Goodwin, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|February 27, 2021
The clinical effectiveness of using a predictive algorithm to guide antidepressant treatment in primary care (PReDicT): an open-label, randomised controlled trialMichael Browning, Amy C Bilderbeck, Rebecca Dias, et al.
Cancer Research|November 8, 2022
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic CancerCraig M Goodwin, Andrew M Waters, Jennifer E Klomp, et al.
Science Signaling|August 9, 2022
Functional and biological heterogeneity of KRAS<sup>Q61</sup> mutationsMinh V Huynh, G Aaron Hobbs, Antje Schaefer, et al.
Science Advances|October 1, 2021
GABARAP sequesters the FLCN-FNIP tumor suppressor complex to couple autophagy with lysosomal biogenesisJonathan M Goodwin, Ward G Walkup, Kirsty Hooper, et al.
FEBS Letters|November 24, 2016
Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitorsTaekyu Lee, Zhiguo Bian, Bin Zhao, et al.
Pageof 86